Optimal timing of chemotherapy in androgen independent prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 1, 2009, Pages 97-100

  Schnadig, Ian D ^a   Beer, Tomasz M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Androgen; Cancer; Chemotherapy; Docetaxel; Hormone; Metastatic; Prostate; Prostatic neoplasm

Indexed keywords

ABIRATERONE; ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; G VAX; GONADORELIN DERIVATIVE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE METASTASIS; BONE PAIN; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONOTHERAPY; CLINICAL TRIAL; DRUG FATALITY; HUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ANDROGENS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS;

EID: 57849113149     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.04.004     Document Type: Review

References (16)

1. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
2. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
3. Basch E.M., Somerfield M.R., Beer T.M., et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 25 (2007) 5313-5318
4. Scardino P. Update: NCCN Prostate Cancer Clinical Practice Guidelines. J Natl Compr Cancer Network 3 Suppl 1 (2005) S29-S33
5. Winquist E., Waldron T., Berry S., et al. Nonhormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: A systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 6 (2006) 112
6. Schellhammer P.F., Venner P., Haas G.P., et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 157 (1997) 1731-1735
7. Ryan C.J., and Small E.J. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep 7 (2005) 228-233
8. Smith M.R., Kabbinavar F., Saad F., et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23 (2005) 2918-2925
9. Dreicer R., and Carducci M. E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels. Rev Urol 5 Suppl 2 (2003) S35-S41
10. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21 (2003) 1232-1237
11. Berthold D.R. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study. J Clin Oncol 25 (2007) 5005 [Abstract]
12. Pond G.R. Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol 24 (2006) 4557 [Abstract]
13. U.S. National Institutes of Health Clinical Trials. http://clinicaltrials.gov accessed December 7, 2007
14. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
15. Fizazi K. The GETUG 12 trial, a Phase III randomized trial of docetaxel-estramustine in high-risk localized prostate cancer: Clinical design and current status. In: Proceedings of the American Society of Clinical Oncology Prostate Cancer Symposium (ASCO), Atlanta (GA), June, 2006 [Abstract 153].
16. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507